ESPECIALIDADES viernes, 23 febrero / 2024  
Reumatología
Portal de Infomed
 
 
Total de artículos: 726 mostrando: 191 - 200

página 20 de 73   11  12  13  14  15  16  17  18  19  20  
Titulares

A clinical exploratory study with Itolizumab, an anti-CD6 monoclonal antibody, in patients with rheumatoid arthritis

A clinical exploratory study with Itolizumab, an anti-CD6 monoclonal antibody, in patients with rheumatoid arthritis

immunologyPedro C. Rodriguez, Roberto Torres-Moya, Gil Reyes, Claudino Molinero, Dinorah Prada, Ana M. Lopez, Isabel M. Hernandez, Maria V. Hernandez, Jose P. Martinez, Xochel Hernandez, Angel Casaco, Mayra Ramos, Yisel Avila, Yinet Barrese, Enrique Montero, Patricia Hernandez.

T cells are involved in the pathogenesis of rheumatoid arthritis (RA). CD6 is a co-stimulatory molecule, predominantly expressed on lymphocytes, that has been linked to autoreactive responses. The purpose of this study was to evaluate the safety, immunogenicity and preliminary efficacy of itolizumab, a humanized anti-CD6 monoclonal antibody, in patients with active rheumatoid arthritis. Fifteen patients were enrolled in a phase I, open-label, dose-finding study. Five cohorts of patients received a weekly antibody monotherapy with a dose-range from 0.1 to 0.8mg/kg. Itolizumab showed a good safety profile, with no severe or serious adverse events reported so far. No signs or symptoms associated with immunosuppression were observed in the study.Objective clinical responseswere achieved inmore than 80% of patients after treatment completion, and these responses tend to be sustained afterwards. This clinical study constitutes the first evidence of the safety and positive clinical effect of a monotherapy using an anti-CD6 antibody in patients with rheumatoid arthritis.


 
Total de artículos: 726 mostrando: 191 - 200

página 20 de 73   11  12  13  14  15  16  17  18  19  20  
 
: Editor Principal, Especialista de II Grado en Reumatología, Profesor auxiliar e Investigador agregado | Facultad de medicina “Dr. Miguel Enríquez”, Laboratorio central de líquido cefalorraquídeo (LABCEL), MINSAP | Ramón Pinto #202. 10 de Octubre, La Habana, 19700, Cuba | Teléfs.: (537) 6902087 Horario de atención: lunes a viernes, de 8:30 a.m. a 5:00 p.m.


Nosotros suscribimos Los Principios del código HONcode de la Fundación Salud en la Red
 Nosotros suscribimos
 los Principios
 HONcode.
 Compruébelo aquí
Webs Médicas de Calidad Contenido Digital Cubano 2005 Premio Stockholm Challenge 2002